Terms: = Prostate cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1
255 results:
1. Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells.
Wu Y; Liu P; Chen W; Bai S; Chen S; Chen J; Xu X; Xia J; Wu Y; Lai J; Sun C; Lao Z; Wan X; Wu Z
Int J Hyperthermia; 2024; 41(1):2335201. PubMed ID: 38583875
[TBL] [Abstract] [Full Text] [Related]
2. [
Schaefer-Schuler A; Burgard C; Blickle A; Maus S; Petrescu C; Petto S; Bartholomä M; Stemler T; Ezziddin S; Rosar F
Theranostics; 2024; 14(5):1829-1840. PubMed ID: 38505615
[No Abstract] [Full Text] [Related]
3. Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for prostate cancer Therapy.
Oliveira M; Sousa A; Sá S; Soares S; Pereira AC; Rocha AC; Pais P; Ferreira D; Almeida C; Luís C; Lima C; Almeida F; Gestoso Á; Duarte MC; Barata P; Martins-Mendes D; Baylina P; Pereira CF; Fernandes R
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396953
[TBL] [Abstract] [Full Text] [Related]
4. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract] [Full Text] [Related]
5. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract] [Full Text] [Related]
6. The Impact of Nutrient Supply on prostate cancer Risk Worldwide.
Jiang J; Yang J; Chen B; Li J; Zhang T; Tan D; Tang B; Wei Q
Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140390
[TBL] [Abstract] [Full Text] [Related]
7. [Work Participation after Multimodal Rehabilitation due to cancer: Representative Analyses using Routine Data of the German Pension Insurance].
Fauser D; Zollmann P; Streibelt M; Bethge M
Rehabilitation (Stuttg); 2024 Apr; 63(2):107-118. PubMed ID: 38065547
[TBL] [Abstract] [Full Text] [Related]
8. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic prostate cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients.
Scheipner L; Incesu RB; Morra S; Baudo A; Assad A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; De Cobelli O; Pichler M; Ahyai S; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):164-170. PubMed ID: 37981546
[TBL] [Abstract] [Full Text] [Related]
10. Development of PARP Inhibitors in Targeting Castration-Resistant prostate cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract] [Full Text] [Related]
11. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
14. Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer.
Chiang YC; Leu WJ; Chen YC; Ye PC; Hsu YT; Hsiao YC; Hsu JL; Chan SH; Hsu LC; Huang HS; Guh JH
Prostate; 2023 Dec; 83(16):1549-1563. PubMed ID: 37583103
[TBL] [Abstract] [Full Text] [Related]
15. Use of the Decipher genomic classifier among men with prostate cancer in the United States.
Zaorsky NG; Proudfoot JA; Jia AY; Zuhour R; Vince R; Liu Y; Zhao X; Hu J; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gershman S; Cheng I; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura M; Schwartz SM; Ward KC; Wiggins C; Wu XC; Shoag JE; Ponsky L; Dal Pra A; Schaeffer EM; Ross AE; Sun Y; Davicioni E; Petkov V; Spratt DE
JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37525535
[TBL] [Abstract] [Full Text] [Related]
16. Veratramine Inhibits the Cell Cycle Progression, Migration, and Invasion via ATM/atr Pathway in Androgen-Independent prostate cancer.
Kim HY; Lee SW; Choi SK; Ashim J; Kim W; Beak SM; Park JK; Han JE; Cho GJ; Ryoo ZY; Jeong J; Lee YH; Jeong H; Yu W; Park S
Am J Chin Med; 2023; 51(5):1309-1333. PubMed ID: 37385965
[TBL] [Abstract] [Full Text] [Related]
17. Factors Associated with Long-Term prostate cancer Survival after Palliative Radiotherapy to a Bone Metastasis and Contemporary Palliative Systemic Therapy: A Retrospective, Population-Based Study.
Venugopal B; Shahhat S; Beck J; Hanumanthappa N; Ong AD; Dubey A; Koul R; Bashir B; Chowdhury A; Sivananthan G; Kim JO
Curr Oncol; 2023 Jun; 30(6):5560-5573. PubMed ID: 37366903
[TBL] [Abstract] [Full Text] [Related]
18. Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: Implications for treatment margins.
Dassen MG; Janssen T; Kusters M; Pos F; Kerkmeijer LGW; van der Heide UA; van der Bijl E
Radiother Oncol; 2023 Sep; 186():109761. PubMed ID: 37348607
[TBL] [Abstract] [Full Text] [Related]
19. Are magnetic resonance imaging and targeted biopsies needed in men with serum prostate-specific antigen over 10 ng/ml and an abnormal digital rectal examination?
Morote J; Picola N; Paesano N; Celma A; Muñoz-Rodriguez J; Asiain I; Ruiz-Plazas X; Muñoz-Rivero MV; de Manuel GG; Servian P; Abascal JM
Urol Oncol; 2023 Jul; 41(7):299-301. PubMed ID: 37244767
[TBL] [Abstract] [Full Text] [Related]
20. Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Abel ML; Takahashi N; Peer C; Redon CE; Nichols S; Vilimas R; Lee MJ; Lee S; Shelat M; Kattappuram R; Sciuto L; Pinkiert D; Graham C; Butcher D; Karim B; Sharma AK; Malin J; Kumar R; Schultz CW; Goyal S; Del Rivero J; Krishnamurthy M; Upadhyay D; Schroeder B; Sissung T; Tyagi M; Kim J; Pommier Y; Aladjem M; Raffeld M; Figg WD; Trepel J; Xi L; Desai P; Thomas A
Clin Cancer Res; 2023 Sep; 29(18):3603-3611. PubMed ID: 37227187
[TBL] [Abstract] [Full Text] [Related]
[Next]